Oncology continues to be the leading therapeutic area across the biopharma industry by almost all measures, including global drug sales, number of pipeline programs, venture capital dollar deployment, business development activity, and number of drug approvals. Innovation within the oncology pipeline continues to flourish, with novel mechanisms helping counteract the impending loss of exclusivity for several of today’s leading products. But where do industry leaders anticipate future investment to be heading? How are trends in discovery, development, commercialization, and business development impacting how large, mid-size, and small biopharma approach opportunities in oncology? A panel of experts will discuss what the industry can expect in oncology for the remainder of 2026 and beyond.